Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer
Clinical trial NCT04164745 · UNKNOWN
Trial details
- NCT number
- NCT04164745
- Sponsor
- Peking Union Medical College Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-16
- Primary completion
- 2021-11-16
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.